AJP - Regu Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Regul Integr Comp Physiol 282: R1395-R1404, 2002. First published January 17, 2002; doi:10.1152/ajpregu.00597.2001
0363-6119/02 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/5/R1395    most recent
00597.2001v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (19)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reidelberger, R. D.
Right arrow Articles by Heimann, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reidelberger, R. D.
Right arrow Articles by Heimann, D.
Vol. 282, Issue 5, R1395-R1404, May 2002

Effects of amylin-related peptides on food intake, meal patterns, and gastric emptying in rats

Roger D. Reidelberger, Linda Kelsey, and Dean Heimann

Veterans Administration Medical Center, Omaha 68105; and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska 68178


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

We previously demonstrated that amylin inhibits food intake and gastric emptying in rats with half-maximal effective doses (ED50s) of 8 and 3 pmol · kg-1 · min-1 and maximal inhibitions of 78 and 60%, respectively. In this study of identical design, rats received intravenous infusions of salmon calcitonin (sCT), rat calcitonin (rCT), rat calcitonin gene-related peptide (rCGRP), and rat adrenomedullin (rADM) for 3 h at dark onset, and food intake was measured for 17 h or for 15 min and gastric emptying of saline was measured during the final 5 min. sCT, rCGRP, and rADM inhibited food intake with estimated ED50s of 0.5, 26, and 35 pmol · kg-1 · min-1 and maximal inhibitions of 88, 90, and 49%, respectively. rCT was not effective at doses up to 100 pmol · kg-1 · min-1. sCT, rCGRP, rADM, and rCT inhibited gastric emptying with ED50s of 1, 130, 160, and 730 pmol · kg-1 · min-1 and maximal inhibitions of 60, 66, 60, and 33%, respectively. These results suggest that amylin and sCT may act by a common mechanism to decrease food intake, which includes inhibition of gastric emptying.

calcitonin; calcitonin gene-related peptide; adrenomedullin; anorexia; potency


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

AMYLIN (ALSO CALLED ISLET amyloid polypeptide) is a 37- amino acid peptide that is cosecreted with insulin from the pancreas in response to a meal (11, 51). Amylin has also been detected in gut endocrine cells (35), visceral sensory neurons (36), and throughout the brain (44). Exogenous amylin potently reduces food intake (1, 3, 39), body weight (1), adiposity (41), gastric emptying (10, 39), and gastric acid secretion (15) when administered systemically or into the brain. We recently demonstrated that the minimal effective intravenous dose for amylin-induced inhibition of food intake and gastric emptying in rats (1 pmol · kg-1 · min-1) increases plasma amylin by an amount comparable to that produced by a meal (3, 39). We also demonstrated that in suppressing feeding and gastric emptying, amylin is at least as potent and efficacious as CCK (39), a physiological inhibitor of food intake and gastric emptying. These results support the hypothesis that amylin acts as a hormonal signal to the brain to inhibit gastric emptying and food intake and that amylin produces satiety, in part, through inhibition of gastric emptying.

Calcitonin gene-related peptide (CGRP), calcitonin (CT), and adrenomedullin (ADM), together with amylin, form a family of structurally related peptides with overlapping biological actions (Fig. 1). Each of these peptides inhibits food intake (13, 22, 32, 45) and gastric emptying (8, 20, 30, 38) when administered systemically or into the brain. The teleost peptide salmon CT (sCT) appears to be significantly more potent than either amylin (29) or mammalian CTs (8, 29, 47) in decreasing food intake and gastric emptying. No study has directly compared the effects of systemic administration of these amylin-related peptides on food intake and gastric emptying in the same species. Factors that inhibit gastric emptying can indirectly reduce food intake by promoting gastric distention. If the anorexia produced by these amylin-related peptides is due, in part, to inhibition of gastric emptying, then it would be important to determine for each peptide whether its potency for reducing gastric emptying is greater than or equal to its potency for reducing food intake. Lutz et al. (26) concluded that amylin does not reduce food intake by inhibiting gastric emptying because they observed that a single anorexic dose of amylin had no effect on gastric emptying of spontaneous meals. In contrast, we recently demonstrated that amylin inhibits food intake and gastric emptying of a nonnutrient liquid with a similar potency and efficacy (39). The aims of the present study were to determine the dose-response effects of intravenous infusions of rat (r) CGRP, CT, ADM, and sCT on food intake and gastric emptying in rats and to compare these effects with those of rat amylin, which were determined previously using an identical experimental design (39).


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 1.   Alignment of the amino acid sequences of rat amylin (rAMY), rat calcitonin gene-related peptide (rCGRP), salmon calcitonin (sCT), rat calcitonin (rCT), and rat adrenomedullin (rADM). Amino acids that are enclosed within a box are the same as those found in rAMY.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Subjects. Adult male Sprague-Dawley rats (Sasco, Charles River), weighing 350-400 g at the time of surgery, were housed individually in hanging wire mesh cages in a temperature-controlled room with a 12:12-h light-dark cycle (lights off at 1700). Eight separate experiments were performed. The first series of four experiments determined the dose-dependent effects of 3-h intravenous infusions of sCT, rCT, rCGRP, and rADM at dark onset on food intake and meal patterns in nonfood-deprived rats. The second series of four experiments determined the dose-dependent effects of 15-min intravenous infusions of sCT, rCT, rCGRP, and rADM on gastric emptying of a 3-ml saline load during a 5-min period in unanesthetized rats. The Animal Studies Subcommittee of the Omaha Veterans Administration Medical Center approved the experimental protocol.

Surgical procedures. The procedures for implantation of a jugular vein catheter for peptide infusions were described previously (52). Catheters were filled with heparinized saline (40 U/ml), plugged with stainless steel wire, and flushed with 0.5 ml of heparinized saline every other day to maintain patency. In animals used for feeding studies, jugular vein catheters were connected to 40-cm lengths of tubing passed through a protective spring coil connected between a lightweight saddle (IITC, Woodland Hills, CA) worn by the rat and an infusion swivel. The procedures for implantation of a gastric cannula for instillation of saline and retrieval of gastric contents were described previously (39).

Effects of intravenous infusions of sCT, rCT, rCGRP, and rADM on food intake and meal patterns. Excess amounts of fresh food were provided each day at 1400. Animals were adapted to experimental conditions for at least 1 wk before the start of experiments. Nonfood-deprived rats received a 3-h jugular vein infusion (3 ml/h) of sCT (Peninsula Laboratories; 0, 0.1, 0.3, 1, 3, or 10 pmol · kg-1 · min-1 in 0.15 M NaCl, 0.1% BSA) beginning 15 min before dark onset (1700). Food intake and meal patterns during the first 17 h after onset of infusion were determined, as described previously, from continuous computer recordings of changes in food bowl weight (52). For each experiment, individual meals were defined using a minimum meal size criterion of 50 mg and a minimum intermeal interval criterion of 5 min. Infusions were administered via a syringe infusion pump (model 22, Harvard Apparatus, South Natick, MA); pumps were turned on and off by a computer program. Each rat (n = 9) received each dose of sCT in random order at intervals of least 48 h.

In separate experiments of identical design for each peptide, rats randomly received a series of doses (0, 3, 10, 30, and 100 pmol · kg-1 · min-1) of rCT (Peninsula Laboratories; n = 9), rCGRP (Peninsula Laboratories; n = 12), and rADM (Peninsula Laboratories; n = 12).

Effects of intravenous infusions of sCT, rCT, rCGRP, and rADM on gastric emptying. The experimental design was similar to that described previously (39). Rats with gastric and jugular vein cannulas were adapted to a 17-h fast, followed by light restraint in a Bollman-type cage, flushing of the stomach with warm saline, and a 15-min intravenous infusion (3.2 ml/h) of 0.15 M NaCl, 0.1% BSA. On experimental days, the food-deprived rats received a 15-min jugular vein infusion of sCT (0, 1, 3, or 10 pmol · kg-1 · min-1 in 0.15 M NaCl, 0.1% BSA). Ten minutes after infusion onset, 3 ml of saline containing 60 mg/ml phenol red were instilled into the stomach. Gastric contents were recovered 5 min later through the gastric cannula, the volume was measured, and the concentration of phenol red was determined spectrophotometrically to provide a measure of the amount of saline emptied during the 5-min period. Each rat (n = 10) received each dose of sCT in random order at intervals of at least 48 h.

In separate experiments of identical design for each peptide, rats randomly received a series of doses (0, 50, 170, and 500 pmol · kg-1 · min-1) of rCT (n = 10), rCGRP (n = 12), and rADM (n = 10).

Statistical analyses. Values are presented as group means ± SE. For the feeding experiments, we separately evaluated the dose-dependent effects of jugular vein infusions of sCT, rCT, rCGRP, and rADM on amount of food ingested each hour, food intake cumulated hourly across the 17-h test period, first meal parameters [latency, meal size, postmeal interval, and satiety ratio (postmeal interval/meal size)], and mean meal parameters across the 3-h infusion period [number of meals, meal size, postmeal interval, satiety ratio, and eating rate (meal size/meal duration)] by repeated-measures ANOVA, with peptide dose and time being the within-group factors. For the gastric emptying experiments, the dose-dependent effects of jugular vein infusions of sCT, rCT, rCGRP, and rADM on volume of saline emptied from the stomach in 5 min were evaluated separately using a repeated-measures ANOVA, with peptide dose being the within-group factor. Planned comparisons of treatment means were evaluated by direct contrasts of means with the statistical program SYSTAT. In each analysis, differences were considered significant if P < 0.05. A one-tailed test was used for the postulated unidirectional effects of each peptide.

A general nonlinear, least-squares curve-fitting method was used as previously described (12) to fit the dose-response data for the effects of sCT, rCT, rCGRP, and rADM on food intake and gastric emptying to the following logistic equation: Y = (a - d)/[1 + (X/c)b] + d, where Y is the response; X, the dose; a, the response for 0 dose; d, the response for infinite dose; c, the ED50 (dose producing response halfway between a and d); and b, a slope factor that determines steepness of the curve. The method of Meddings et al. (31) was used to compare the relative potencies (ED50s) and efficacies of sCT, rCT, rCGRP, and rADM for inhibition of feeding and gastric emptying with those of amylin, which we recently determined using an identical experimental protocol (39).


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Effects of intravenous infusions of sCT, rCT, rCGRP, and rADM on food intake. sCT infusion for 3 h at dark onset dose dependently inhibited cumulative food intake across the 17-h test period (Fig. 2). The minimal effective dose (0.1 pmol · kg-1 · min-1), the lowest dose administered, inhibited cumulative intake at 2, 3, and 4 h by 27% (P < 0.05), 25% (P < 0.05), and 17% (P < 0.05), respectively. The maximal effective dose (10 pmol · kg-1 · min-1), the largest dose administered, decreased cumulative intake throughout the 17-h test period, with a peak inhibition of 100% at 1 h (P < 0.001), decreasing to 85% inhibition by 17 h (P < 0.001). In this experiment, each rat received all doses of sCT in random order at 48-h intervals. We measured food intake on intervening days when sCT was not administered to determine if there was a carry-over effect of the peptide on food intake between the experimental days. The day before the sCT experiment began, food intake was 26.8 ± 1.7 g. Food intake on days immediately following delivery of the 0, 0.1, 0.3, 1, 3, and 10 pmol · kg-1 · min-1 doses was 23.8 ± 1.0, 24.3 ± 1.4, 26.0 ± 2.5, 25.6 ± 1.2, 27.8 ± 1.6, and 24.9 ± 2.2 g, respectively. These data clearly show that food intake returned to normal within 48 h of sCT administration.


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 2.   Food intake response to intravenous infusion of sCT in 9 rats. Nonfood-deprived rats received a 3-h intravenous infusion of sCT beginning 15 min before dark onset. *P < 0.05, dagger P < 0.01, or Dagger P < 0.001 compared with 0-pmol · kg-1 · min-1 dose of sCT.

Figure 3 shows the dose-response effects of sCT on intake during the 3-h infusion period. Nonlinear regression fitting of the data to the logistic equation gave the following relationship between cumulative intake in grams and sCT dose in picomoles per kilogram per minute: food intake = 7.6 g/[1 + (sCT/0.5 pmol · kg-1 · min-1)0.94] + 0.1 g (goodness of fit r2 = 0.86). Thus sCT inhibited food intake during the 3-h infusion period with a threshold dose <0.1 pmol · kg-1 · min-1 and an estimated ED50 of 0.5 pmol · kg-1 · min-1. For comparison, Fig. 3 also shows the dose-response effects of intravenous infusion of amylin on 3-h cumulative intake using an identical experimental procedure (39). The ED50 for sCT is significantly smaller than that for amylin (0.5 vs. 8 pmol · kg-1 · min-1; F1,133 = 51.1, P < 0.0001); maximal inhibitory responses to sCT and amylin are not different (F1,132 = 0.8, P = 0.37).


View larger version (20K):
[in this window]
[in a new window]
  		Fig. 3.   Dose-response effects of rAMY, sCT, rCGRP, rADM, and rCT on 3-h food intake. Individual curves represent nonlinear regression fitting of data to a logistic equation. Resulting best-fit equations were as follows: rAMY: food intake (g) = 5.5 g/[1 + (rAMY dose/8.0 pmol · kg-1 · min-1)1.4] + 1.4 g; sCT: food intake (g) = 7.6 g/[1 + (sCT dose/0.5 pmol · kg-1 · min-1)0.94] + 0.1 g; rCGRP: food intake (g) = 5.6 g/[1 + (rCGRP dose/26 pmol · kg-1 · min-1)1.3]; and rADM: food intake (g) = 4.1 g/[1 + (rADM dose/35 pmol · kg-1 · min-1)1.3] + 2.6 g. *P < 0.05, dagger P < 0.01, or Dagger P < 0.001 compared with 0-pmol · kg-1 · min-1 dose of the same peptide.

rCT infusion for 3 h at dark onset at doses from 3 to 100 pmol · kg-1 · min-1 had no significant effect on food intake (Figs. 3 and 4).


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 4.   Food intake response to intravenous infusion of rCT in 9 rats. Nonfood-deprived rats received a 3-h intravenous infusion of rCT beginning 15 min before dark onset.

rCGRP infusion for 3 h at dark onset dose dependently inhibited cumulative food intake across the 17-h test period (Fig. 5). The minimal effective dose (10 pmol · kg-1 · min-1) inhibited cumulative intake at 1, 2, and 3 h by 56% (P < 0.05), 47% (P < 0.01), and 30% (P < 0.01), respectively. The maximal effective dose (100 pmol · kg-1 · min-1), the largest dose administered, decreased cumulative intake throughout the first 10 h of the 17-h test period, with a peak inhibition of 89% at 1 h (P < 0.001), decreasing to 12% by 10 h (P < 0.05). Figure 3 shows the dose-response effects of rCGRP on intake during the 3-h infusion period. Nonlinear regression fitting of the data to the logistic equation gave the following relationship between cumulative intake in grams and rCGRP dose in picomoles per kilogram per minute: food intake = 5.6 g/[1 + (rCGRP/26 pmol · kg-1 · min-1)1.3] (goodness of fit r2 = 0.82). Thus rCGRP inhibited food intake during the 3-h infusion period with a threshold dose between 3 and 10 pmol · kg-1 · min-1 and an estimated ED50 of 26 pmol · kg-1 · min-1. The ED50 for rCGRP is significantly larger than that for sCT (26 vs. 0.5 pmol · kg-1 · min-1; F1,108 = 45.5, P < 0.0001); maximal inhibitory responses to rCGRP and sCT are not different (F1,107 = 0.07, P = 0.79). The ED50 and maximal response for rCGRP are not different from those for amylin (F1,139 = 0.09, P = 0.76 and F1,138 = 0.67, P = 0.41, respectively).


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 5.   Food intake response to intravenous infusion of rCGRP in 12 rats. Nonfood-deprived rats received a 3-h intravenous infusion of rCGRP beginning 15 min before dark onset. *P < 0.05, dagger P < 0.01, or Dagger P < 0.001 compared with 0-pmol · kg-1 · min-1 dose of rCGRP.

rADM infusion for 3 h at dark onset dose dependently inhibited cumulative food intake across the 17-h test period (Fig. 6). The minimal effective dose (30 pmol · kg-1 · min-1) inhibited cumulative intake at 3 and 4 h by 29% (P < 0.001) and 14% (P < 0.05), respectively. The maximal effective dose (100 pmol · kg-1 · min-1), the largest dose administered, decreased cumulative intake throughout the first 10 h of the 17-h test period, with a peak inhibition of 69% at 1 h (P < 0.01), decreasing to 12% by 10 h (P < 0.05). Figure 3 shows the dose-response effects of rADM on intake during the 3-h infusion period. Nonlinear regression fitting of the data to the logistic equation gave the following relationship between cumulative intake in grams and rADM dose in picomoles per kilogram per minute: food intake = 4.1 g/[1 + (rADM/35 pmol · kg-1 · min-1)1.3] + 2.6 g (goodness of fit r2 = 0.94). Thus rADM inhibited food intake during the 3-h infusion period with a threshold dose between 10 and 30 pmol · kg-1 · min-1 and an estimated ED50 of 35 pmol · kg-1 · min-1. The ED50 for rADM is significantly larger than that for sCT (35 vs. 0.5 pmol · kg-1 · min-1; F1,139 = 24.8, P < 0.0001), amylin (35 vs. 8 pmol · kg-1 · min-1; F1,108 = 104, P < 0.0001), and rCGRP (35 vs. 26 pmol · kg-1 · min-1; F1,116 = 30, P < 0.0001). The maximal inhibitory response to rADM is not different from that to sCT, rCGRP, and amylin (rADM vs. sCT: F1,138 = 0.9, P = 0.34; rADM vs. rCGRP: F1,115 = 0.26, P = 0.61; and rADM vs. amylin: F1,107 = 1.21, P = 0.27).


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 6.   Food intake response to intravenous infusion of rADM in 12 rats. Nonfood-deprived rats received a 3-h intravenous infusion of rADM beginning 15 min before dark onset. *P < 0.05, dagger P < 0.01, or Dagger P < 0.001 compared with 0-pmol · kg-1 · min-1 dose of rADM.

Effects of intravenous infusion of sCT, rCT, rCGRP, and rADM on meal patterns. Lower doses of sCT (<= 0.3 pmol · kg-1 · h-1) reduced food intake primarily by decreasing mean meal size during the 3-h infusion period (Table 1). Higher doses increased the latency to the first meal and reduced meal size and meal frequency. sCT had no significant effect on average eating rate during meals, as determined by dividing meal size by meal duration (data not shown).

                              
View this table:
[in this window]
[in a new window]
  		Table 1.   Effects of intravenous infusions of sCT, rCGRP, rADM, and rCT on meal patterns

The two highest doses of ADM (30 and 100 pmol · kg-1 · min-1) reduced meal frequency and the size of the first meal following infusion onset (Table 1). CGRP reduced meal frequency at the 10- and 100-pmol · kg-1 · min-1 doses and reduced average meal size at the 30- and 100-pmol · kg-1 · min-1 doses. The highest dose of rCGRP significantly reduced eating rate during meals that were consumed during the 3-h infusion period (data not shown). However, only an average of 0.4 meals were consumed during this period, compared with 2.9 meals when vehicle was infused. rCT had no effect on meal size or frequency at any of the doses tested (Table 1).

Effects of intravenous infusion of sCT, rCT, rCGRP, and rADM on gastric emptying. sCT dose dependently reduced the volume of saline emptied from the stomach during the 5-min test period (Fig. 7; F3,27 = 19.9, P < 0.001). The minimal effective dose (1 pmol · kg-1 · min-1), which was the lowest dose given, decreased emptying by 32% (P < 0.001). The maximal effective dose (10 pmol · kg-1 · min-1), the largest dose given, decreased emptying by 60% (P < 0.001). Nonlinear regression fitting of the data to the logistic equation gave the following relationship between gastric emptying in milliliters and sCT dose in picomoles per kilogram per minute: gastric emptying = 2.1 ml/[1 + (sCT/1.0 pmol · kg-1 · min-1)1.1] + 0.9 ml (goodness of fit r2 = 0.91). Thus sCT inhibited gastric emptying with a threshold dose <1 pmol · kg-1 · min-1 and an estimated ED50 of 1 pmol · kg-1 · min-1. For comparison, Fig. 7 also shows the dose-response effects of intravenous infusion of amylin on gastric emptying using an identical experimental procedure (39). The estimated ED50 for sCT is significantly smaller than that for amylin (1 vs. 2.9 pmol · kg-1 · min-1; F1,83 = 10.6, P = 0.0016); maximal inhibitory responses to sCT and amylin are not different (F1,82 = 2.0, P = 0.16).


View larger version (18K):
[in this window]
[in a new window]
  		Fig. 7.   Gastric emptying responses to intravenous infusions of rAMY, sCT, rCGRP, rADM, and rCT in 12, 10, 12, 10, and 10 rats, respectively. Eighteen-hour food-deprived rats received a 15-min intravenous infusion of peptide beginning 10 min before gastric instillation of 3 ml of saline containing phenol red. Gastric contents were recovered 5 min later. Individual curves represent nonlinear regression fitting of data to a logistic equation. Resulting best-fit equations were as follows: rAMY: volume emptied (ml) = 1.3 ml/[1 + (rAMY dose/2.9 pmol · kg-1 · min-1)1.0] + 0.9 ml; sCT: volume emptied (ml) = 2.1 ml/[1 + (sCT dose/1.0 pmol · kg-1 · min-1)1.1] + 0.9 ml; rCGRP: 2.0 ml/[1 + (rCGRP dose/130 pmol · kg-1 · min-1)1.9] + 0.9 ml; rADM: 2.0 ml/[1 + (rADM dose/160 pmol · kg-1 · min-1)2.3] + 0.7 ml; and rCT: 2.0 ml/[1 + (rCT dose/730 pmol · kg-1 · min-1)1.9] + 0.9 ml. *P < 0.05 and Dagger P < 0.001 compared with 0- pmol · kg-1 · min-1 dose of the same peptide.

rCGRP dose dependently reduced the volume of saline emptied from the stomach during the 5-min test period (Fig. 7; F3,33 = 33.8, P < 0.001). The minimal effective dose (170 pmol · kg-1 · min-1) decreased emptying by 44% (P < 0.001). The maximal effective dose (500 pmol · kg-1 · min-1), the largest dose given, decreased emptying by 66% (P < 0.001). Nonlinear regression fitting of the data to the logistic equation gave the following relationship between gastric emptying in milliliters and rCGRP dose in picomoles per kilogram per minute: gastric emptying = 2 ml/[1 + (rCGRP/130 pmol · kg-1 · min-1)1.9] + 0.9 ml (goodness of fit r2 = 0.94). Thus rCGRP inhibited gastric emptying with a threshold dose between 50 and 170 pmol · kg-1 · min-1 and an estimated ED50 of 130 pmol · kg-1 · min-1. The ED50 for rCGRP is significantly larger than that for sCT (130 vs. 1 pmol · kg-1 · min-1; F1,83 = 40, P < 0.0001) and amylin (130 vs. 2.9 pmol · kg-1 · min-1; F1,91 = 106, P < 0.0001). The maximal inhibitory response to rCGRP is not different from that to sCT and amylin (rCGRP vs. sCT: F1,82 = 0.05, P = 0.82; rCGRP vs. amylin: F1,90 = 3.9, P = 0.051).

rADM dose dependently reduced the volume of saline emptied from the stomach during the 5-min test period (Fig. 7; F3,33 = 33.8, P < 0.001). The minimal effective dose (170 pmol · kg-1 · min-1) decreased emptying by 35% (P < 0.001). The maximal effective dose (500 pmol · kg-1 · min-1), the largest dose given, decreased emptying by 60% (P < 0.001). Nonlinear regression fitting of the data to the logistic equation gave the following relationship between gastric emptying in milliliters and rADM dose in picomoles per kilogram per minute: gastric emptying = 2 ml/[1 + (rADM/160 pmol · kg-1 · min-1)2.3] + 0.7 ml (goodness of fit r2 = 0.95). Thus rADM inhibited gastric emptying with a threshold dose between 50 and 170 pmol · kg-1 · min-1 and an estimated ED50 of 160 pmol · kg-1 · min-1. The ED50 for rADM is significantly larger than that for sCT (160 vs. 1 pmol · kg-1 · min-1; F1,75 = 47, P < 0.0001) and amylin (160 vs. 2.9 pmol · kg-1 · min-1; F1,83 = 50, P < 0.0001), and it is similar to that for rCGRP (160 vs. 130 pmol · kg-1 · min-1; F1,83 = 2.4, P = 0.12). The maximal inhibitory response to rADM is not different from that to sCT, rCGRP, and amylin (rADM vs. sCT: F1,74 = 0.11, P = 0.74; rADM vs. amylin: F1,82 = 2.6, P = 0.11; and rADM vs. rCGRP: F1,82 = 0.06, P = 0.81).

rCT dose dependently reduced the volume of saline emptied from the stomach during the 5-min test period (Fig. 7; F3,27 = 7.5, P < 0.001). The minimal effective dose (170 pmol · kg-1 · min-1) decreased emptying by 21% (P < 0.05). The maximal effective dose (500 pmol · kg-1 · min-1), the largest dose given, decreased emptying by 33% (P < 0.001). Nonlinear regression fitting of the data to the logistic equation gave the following relationship between gastric emptying in milliliters and rCT dose in picomoles per kilogram per minute: gastric emptying = 2 ml/[1 + (rCT/730 pmol · kg-1 · min-1)1.9] + 0.9 ml (goodness of fit r2 = 0.99). Thus rCT inhibited gastric emptying with a threshold dose between 50 and 170 pmol · kg-1 · min-1 and an estimated ED50 of 730 pmol · kg-1 · min-1. The ED50 for rCT is significantly larger than that for sCT (730 vs. 1 pmol · kg-1 · min-1; F1,75 = 40, P < 0.0001), amylin (730 vs. 2.9 pmol · kg-1 · min-1; F1,84 = 57, P < 0.0001), rCGRP (730 vs. 130 pmol · kg-1 · min-1; F1,83 = 16, P = 0.01), and rADM (730 vs. 160 pmol · kg-1 · min-1; F1,75 = 5.6, P < 0.05). The maximal inhibitory response to rCT is not different from that to sCT, amylin, rCGRP, and rADM (rCT vs. sCT: F1,74 = 0.1, P = 0.75; rCT vs. amylin: F1,82 = 1.0, P = 0.31; rCT vs. rCGRP: F1,82 = 0.22, P = 0.64; and rCT vs. rADM: F1,74 = 0.41, P = 0.52).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The present study demonstrates that when sCT, rCGRP, rADM, and rCT are administered by continuous intravenous infusion to nonfood-deprived rats during the first 3 h of the dark period, sCT, rCGRP, and rADM dose dependently inhibit food intake during the infusion period with estimated ED50s of 0.5, 26, and 35 pmol · kg-1 · min-1 and maximal inhibitions of 88, 90, and 49%, respectively. In contrast, rCT has no effect at doses up to 100 pmol · kg-1 · min-1. We previously demonstrated that under identical experimental conditions, rat amylin inhibits food intake with an estimated ED50 of 8 pmol · kg-1 · min-1 and a maximal inhibition of 78%. Thus the rank order of potency for the anorexic effects of these structurally related peptides is sCT > amylin > rCGRP > rADM > rCT. Lutz et al. (29) reported a similar rank order of potency for sCT, rat amylin, and rCT when administered to rats by bolus intraperitoneal injection. In contrast, Morley et al. (32, 33) reported similar potencies for amylin and rCGRP when administered by bolus intraperitoneal injection to rodents. Our work clearly shows that amylin inhibits feeding at lower doses and for a longer duration than rCGRP [present study (Ref. 39)]. These discrepant findings may be due to the use of different mouse strains and bolus doses in the studies by Morley et al (32, 33).

Results from our gastric emptying experiments show that sCT, rCGRP, rADM, and rCT dose dependently inhibit gastric emptying of saline during a 5-min period when peptides are administered by continuous intravenous infusion beginning 10 min before the test period. Estimated ED50s are 1, 130, 160, and 730 pmol · kg-1 · min-1 and maximal inhibitions are 60, 66, 60, and 33%, respectively. We previously demonstrated that under identical experimental conditions, amylin inhibits gastric emptying with an ED50 of 3 pmol · kg-1 · min-1 and a maximal inhibition of 60%. Thus the rank order of potency for the inhibitory effects of these structurally related peptides on gastric emptying is sCT > amylin > rCGRP = rADM > rCT. Vine et al. (50) previously demonstrated that sCT is more potent than amylin, and ADM is ineffective, in decreasing gastric emptying when peptides are administered by bolus intraperitoneal injection to rats. Others have reported that sCT is significantly more potent than mammalian CTs in decreasing gastric emptying (8).

Factors that inhibit gastric emptying can indirectly reduce food intake by promoting gastric distention. If the anorexia produced by amylin, sCT, CGRP, and ADM is mediated, in part, through their effect on gastric emptying, then it would be important to determine for each peptide whether its potency for inhibiting gastric emptying is greater than or equal to its potency for inhibiting food intake. We found this to be true for amylin and sCT (3 vs. 8 pmol · kg-1 · min-1 and 1 vs. 0.5 pmol · kg-1 · min-1, respectively) but not for CGRP or ADM (130 vs. 26 pmol · kg-1 · min-1 and 160 vs. 35 pmol · kg-1 · min-1, respectively). rCT had no effect on food intake at doses up to 100 pmol · kg-1 · min-1 and very little effect on gastric emptying at doses up to 500 pmol · kg-1 · min-1. Peptides were infused for a significantly longer period of time in feeding experiments, 180 vs. 15 min in gastric emptying experiments, which may have produced higher peptide levels in tissues and thus more potent effects. Nevertheless, our results are consistent with the hypothesis that sCT and amylin produce anorexia, in part, by inhibiting gastric emptying.

The mechanisms of action of peripherally administered amylin, sCT, CGRP, ADM, and CT on food intake and gastric emptying have not been clearly defined. Several lines of evidence suggest that these peptides may act directly within the brain. 1) Central nervous system (CNS) administration of sCT (13, 20), amylin (1, 5, 10, 41), CGRP (20, 22, 38), and ADM (30) appears to be more potent than systemic administration in reducing food intake and gastric emptying. 2) Subdiaphragmatic vagotomy does not attenuate anorexic responses to sCT (34) and amylin (25, 26). 3) Capsaicin denervation of peripheral sensory nerves does not attenuate the anorexic response to amylin (24). 4) Amylin and ADM can penetrate the blood-brain barrier (6, 21). 5) Area postrema lesions block anorexic responses to amylin and CGRP (28). The effect of vagotomy, capsaicin, and lesioning of the area postrema on gastric emptying responses to amylin-related peptides has not been determined. Most of the studies cited above examined the effects of specific neural lesions on anorexic responses to single intraperitoneal doses that are not likely to be physiological. Other studies of similar design suggest that outcomes can vary depending on the dose of agonist administered. For example, subdiaphragmatic vagotomy has been shown to attenuate the pancreatic exocrine response to physiological, but not pharmacological, doses of the gut peptide CCK (37). Thus it remains to be determined whether gastric emptying and feeding responses to physiological doses of amylin, sCT, and CGRP are mediated by visceral sensory nerves or a direct action of the peptides in the area postrema or some other brain site. It also remains to be determined whether lesions of putative sites of peptide action attenuate a stimulatory effect of antagonists of endogenous peptide action on food intake and gastric emptying.

Recent evidence suggests that the two cloned receptors, the CT receptor (CTR) and the CT receptor-like receptor (CRLR), form the basis of all receptors for sCT, amylin, CGRP, CT, and ADM (42). Unique receptor phenotypes appear to be determined through modification of these receptors by proteins called receptor activity-modifying proteins (RAMPs). The CRLR appears to be transformed by RAMP1 to a relatively high-affinity receptor for CGRP and by RAMP2 (or RAMP3) to a relatively high-affinity receptor for ADM. Similarly, the CTR is transformed by RAMP1 to a relatively high-affinity receptor for amylin and CGRP and by RAMP2 (or RAMP3) to a relatively high-affinity receptor for amylin. In contrast, sCT binds with high affinity to the CTR whether or not it is associated with an RAMP, and CT has at least a two- to threefold lower affinity than sCT to this receptor (9, 19, 46). CTR-RAMP complexes are therefore likely to be the primary mediators of the inhibitory effects of sCT, amylin, CGRP, and ADM on food intake and gastric emptying. CT has a relatively low affinity to these complexes, which may explain its significantly lower potency in reducing food intake and gastric emptying. Receptor autoradiography indicates widespread distributions of high-affinity binding sites for sCT, amylin, CGRP, and ADM in periphery and brain (7, 18, 43, 48). The anatomic distribution of CTR-RAMP receptor complexes has yet to be determined.

If amylin, sCT, CGRP, and ADM act through a common receptor complex to inhibit food intake, then they would be expected to produce similar effects on meal patterns. Our results demonstrate that amylin and sCT do affect meal patterns similarly. Lower doses reduce only meal size, whereas higher doses reduce both meal size and meal frequency. Neither peptide reduces average eating rate during meals as determined by dividing meal size by meal duration. In contrast, ADM appears to reduce meal frequency and the size of the first meal following infusion onset. CGRP also appears to affect both meal frequency and meal size, although the data are somewhat inconsistent. These results suggest a role for at least two different receptor complexes in mediating the effects of amylin, sCT, CGRP, and ADM on food intake.

The present study demonstrates that sCT produces a prolonged suppression of food intake. Three-hour sCT infusions of 0.3, 1, 3, and 10 pmol · kg-1 · min-1 decreased 17-h food intake by 8, 20, 55, and 85%, respectively. Other studies also demonstrated prolonged actions of exogenous sCT on food intake (29) and gastric emptying (8). This unique characteristic of sCT appears to be dependent on its ability to irreversibly bind to the active state of the most common variant of the CTR (16).

CNS administration of ADM has been reported to inhibit food intake and gastric emptying in rats (30, 45). The present study is the first to demonstrate that peripherally administered ADM also reduces food intake and gastric emptying. ADM is a 52-amino acid peptide (rADM has 50 amino acids) that is expressed in virtually every tissue of the body with the possible exception of the thyroid and thymus (18). ADM has a range of biological actions that include vasodilation, cell growth, regulation of hormone secretion, natriuresis, and antimicrobial effects. A growing body of evidence suggests that endogenous ADM does not act like a conventional hormone but rather like an autocrine, paracrine, or neurocrine factor. In the present study, the threshold intravenous doses of rADM for inhibition of feeding (between 10 and 30 pmol · kg-1 · min-1) and gastric emptying (between 50 and 170 pmol · kg-1 · min-1) are significantly larger than ADM doses shown previously to produce hemodynamic and natriuretic effects in rats and humans [1 to 6 pmol · kg-1 · min-1 (23, 49)]. It remains to be determined whether blockade of endogenous ADM action affects food intake or gastric emptying.

An important role for endogenous amylin in the physiological control of food intake and gastric emptying remains to be established. A growing body of evidence suggests that amylin action may be important. In rodents, meal-induced increases in plasma amylin appear to be sufficient to inhibit both food intake and gastric emptying (3, 39). Blockade of endogenous amylin action has also been reported to increase food intake, body weight, and adiposity (2, 14, 40). The mechanism by which food intake stimulates amylin release and the source (pancreas, gut, and brain), mode (endocrine, paracrine, and neurocrine), and site of action (brain, visceral sensory nerves, stomach, and liver) of endogenous amylin to decrease food intake and gastric emptying remain to be determined.

There is little information regarding possible physiological roles for endogenous CGRP and CT in control of food intake and gastric emptying. CGRP-producing cells are widely distributed within the central and peripheral nervous systems (11). CGRP receptor blockade has been reported both to stimulate (27) and to have no effect (2) on food intake. CT appears to be produced primarily by endocrine cells in the thyroid (4). CT is thought to act primarily as a hormone to increase bone resorption and renal Ca2+ excretion in response to a rise in plasma Ca2+ levels. Our results suggest that physiological CT doses are not sufficient to inhibit food intake or gastric emptying. Recently, a sCT-like peptide was isolated from rat diencephalon (17). Thus the possibility exists that an endogenous sCT-like peptide may act as a neurotransmitter or neuromodulator in the brain to inhibit food intake or gastric emptying.

In conclusion, we previously demonstrated that amylin inhibits gastric emptying and food intake in rats with a similar potency (ED50s of 8 and 3 pmol · kg-1 · min-1, respectively). In this study of identical design, only sCT inhibited gastric emptying and food intake with a similar potency (ED50s of 0.5 and 1 pmol · kg-1 · min-1, respectively). Our results also show that amylin and sCT inhibit gastric emptying and food intake with similar efficacies, and they produce similar changes in meal patterns. Previous studies suggest that amylin and sCT act by the same receptor system to inhibit food intake. Together, these results suggest that amylin and sCT may act by a common mechanism to decrease food intake, which includes inhibition of gastric emptying.


    FOOTNOTES

Address for reprint requests and other correspondence: R. Reidelberger, Veterans Administration Medical Center (151), 4101 Woolworth Ave., Omaha, NE 68105.

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

10.1152/ajpregu.00597.2001

Received 1 October 2001; accepted in final form 9 January 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Arnelo, U, Permert J, Adrian TE, Larsson J, Westermark P, and Reidelberger RD. Chronic infusion of islet amyloid polypeptide causes anorexia in rats. Am J Physiol Regulatory Integrative Comp Physiol 271: R1654-R1659, 1996.

2.   Arnelo, U, Permert J, Granqvist L, Adrian TE, Westermark P, Smith DD, and Reidelberger RD. Effects of AC187, IAPP(8-37) and CGRP(8-37) on IAPP-induced anorexia in rats (Abstract). Soc Neurosci Abstr 23: 256, 1997.

3.   Arnelo, U, Reidelberger R, Adrian TE, Larsson J, and Permert J. Sufficiency of postprandial plasma levels of islet amyloid polypeptide for suppression of feeding in rats. Am J Physiol Regulatory Integrative Comp Physiol 275: R1537-R1542, 1998.

4.   Azria, M, Copp DH, and Zanelli JM. 25 Years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 57: 405-408, 1995.

5.   Baldo, BA, and Kelly AE. Amylin infusion into rat nucleus accumbens potently depresses motor activity and ingestive behavior. Am J Physiol Regulatory Integrative Comp Physiol 281: R1232-R1242, 2001.

6.   Banks, WA, Kastin AJ, Maness LM, Huang W, and Jaspan JB. Permeability of the blood-brain barrier to amylin. Life Sci 57: 1993-2001, 1995.

7.   Bhogal, R, Smith DM, and Bloom SR. Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 130: 906-913, 1992.

8.   Bobalik, GR, Kleszynski RR, Aldred JP, Bastian JW, and Schlueter RJ. Differential effects of salmon, porcine, and human calcitonin on gastric secretion and gastric emptying in rats. Proc Soc Exp Biol Med 147: 284-288, 1974.

9.   Christopoulos, G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, Main MJ, Foord SM, and Sexton PM. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56: 235-242, 1999.

10.   Clementi, G, Caruso A, Cutuli VM, de-Bernardis E, Prato A, and Amico-Roxas M. Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia 52: 677-679, 1996.

11.   Cooper, GJ. Amylin compared with calcitonin gene-related peptide: structure, biology, and relevance to metabolic disease. Endocr Rev 15: 163-201, 1994.

12.   DeLean, A, Munson PJ, and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol Endocrinol Metab Gastrointest Physiol 235: E97-E102, 1978.

13.   Freed, WJ, Perlow MJ, and Wyatt RJ. Calcitonin: inhibitory effect on eating in rats. Science 206: 850-852, 1979.

14.   Gebre-Medhin, S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, Sundler F, Ahren B, and Betsholtz C. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250: 271-277, 1998.

15.   Guidobono, F, Coluzzi M, Pagani F, Pecile A, and Netti C. Amylin given by central and peripheral routes inhibits acid gastric secretion. Peptides 15: 699-702, 1994.

16.   Hilton, JM, Dowton M, Houssami S, and Sexton PM. Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors. J Endocrinol 166: 213-226, 2000.

17.   Hilton, JM, Mitchelhill KI, Pozvek G, Dowton M, Quiza M, and Sexton PM. Purification of calcitonin-like peptides from rat brain and pituitary. Endocrinology 139: 982-992, 1998.

18.   Hinson, JP, Kapas S, and Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21: 138-167, 2000.

19.   Houssami, S, Findlay DM, Brady CL, Myers DE, Martin TJ, and Sexton PM. Isoforms of the rat calcitonin receptor: consequences for ligand binding and signal transduction. Endocrinology 135: 183-190, 1994.

20.   Jurgen, LH. Calcitonin and CGRP inhibit gastrointestinal transit via distinct neuronal pathways. Am J Physiol Gastrointest Liver Physiol 254: G920-G924, 1988.

21.   Kastin, AJ, Akerstrom V, Hackler L, and Pan W. Adrenomedullin and the blood-brain barrier. Horm Metab Res 33: 19-25, 2001.

22.   Krahn, DD, Gosnell BA, Levine AS, and Morley JE. Effects of calcitonin gene-related peptide on food intake. Peptides 5: 861-864, 1984.

23.   Lainchbury, JG, Troughton RW, Lewis LK, Yandle TG, Richards AM, and Nicholls MG. Hemodynamic, hormonal, and renal effects of short-term adrenomedullin infusion in healthy volunteers. J Clin Endocrinol Metab 85: 1016-1020, 2000.

24.   Lutz, TA, Althaus J, Rossi R, and Scharrer E. Anorectic effect of amylin is not transmitted by capsaicin-sensitive nerve fibers. Am J Physiol Regulatory Integrative Comp Physiol 274: R1777-R1782, 1998.

25.   Lutz, TA, Del-Prete E, and Scharrer E. Reduction of food intake in rats by intraperitoneal injection of low doses of amylin. Physiol Behav 55: 891-895, 1994.

26.   Lutz, TA, Del-Prete E, and Scharrer E. Subdiaphragmatic vagotomy does not influence the anorectic effect of amylin. Peptides 16: 457-462, 1995.

27.   Lutz, TA, Rossi R, Althaus J, Del-Prete E, and Scharrer E. Evidence for a physiological role of central calcitonin gene-related peptide (CGRP) receptors in the control of food intake in rats. Neurosci Lett 230: 159-162, 1997.

28.   Lutz, TA, Senn M, Althaus J, Del-Prete E, Ehrensperger F, and Scharrer E. Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats. Peptides 19: 309-317, 1998.

29.   Lutz, TA, Tschudy S, Rushing PA, and Scharrer E. Amylin receptors mediate the anorectic action of salmon calcitonin (sCT). Peptides 21: 233-238, 2000.

30.   Martinez, V, Cuttitta F, and Tache Y. Central action of adrenomedullin to inhibit gastric emptying in rats. Endocrinology 138: 3749-3755, 1997.

31.   Meddings, JB, Scott RB, and Fick GH. Analysis and comparison of sigmoidal curves: application to dose-response data. Am J Physiol Gastrointest Liver Physiol 257: G982-G989, 1989.

32.   Morley, JE, Farr SA, and Flood JF. Peripherally administered calcitonin gene-related peptide decreases food intake in mice. Peptides 17: 511-516, 1996.

33.   Morley, JE, and Flood JF. Amylin decreases food intake in mice. Peptides 12: 865-869, 1991.

34.   Morley, JE, Levine AS, Kneip J, and Grace M. The effect of vagotomy on the satiety effects of neuropeptides and naloxone. Life Sci 30: 1943-1947, 1982.

35.   Mulder, H, Ekelund M, Ekblad E, and Sundler F. Islet amyloid polypeptide in the gut and pancreas: localization, ontogeny and gut motility effects. Peptides 18: 771-783, 1997.

36.   Mulder, H, Leckstrom A, Uddman R, Ekblad E, Westermark P, and Sundler F. Islet amyloid polypeptide (amylin) is expressed in sensory neurons. J Neurosci 15: 7625-7632, 1995.

37.   Owyang, C. Physiological mechanisms of cholecystokinin action on pancreatic secretion. Am J Physiol Gastrointest Liver Physiol 271: G1-G7, 1996.

38.   Raybould, HE. Inhibitory effects of calcitonin gene-related peptide on gastrointestinal motility. Ann NY Acad Sci 657: 248-257, 1992.

39.   Reidelberger, RD, Arnelo U, Granqvist L, and Permert J. Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats. Am J Physiol Regulatory Integrative Comp Physiol 280: R605-R611, 2001.

40.   Rushing, PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL, and Woods SC. Inhibition of central amylin signaling increases food intake and body adiposity in rats. Endocrinology 142: 5035-5038, 2001.

41.   Rushing, PA, Hagan MM, Seeley RJ, Lutz TA, and Woods SC. Amylin: a novel action in the brain to reduce body weight. Endocrinology 141: 850-853, 2000.

42.   Sexton, PM, Albiston A, Morfis M, and Tilakaratne N. Receptor activity modifying proteins. Cell Signal 13: 73-83, 2001.

43.   Sexton, PM, Paxinos G, Kenney MA, Wookey PJ, and Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62: 553-567, 1994.

44.   Skofitsch, G, Wimalawansa SJ, Jacobowitz DM, and Gubisch W. Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide-like immunoreactivity in the rat central nervous system. Can J Physiol Pharmacol 73: 945-956, 1995.

45.   Taylor, GM, Meeran K, O'Shea D, Smith DM, Ghatei MA, and Bloom SR. Adrenomedullin inhibits feeding in the rat by a mechanism involving calcitonin gene-related peptide receptors. Endocrinology 137: 3260-3264, 1996.

46.   Tilakaratne, N, Christopoulos G, Zumpe ET, Foord SM, and Sexton PM. Amylin receptor phenotypes derived from human calcitonin receptor/RAMP coexpression exhibit pharmacological differences dependent on receptor isoform and host cell environment. J Pharmacol Exp Ther 294: 61-72, 2000.

47.   Twery, MJ, Obie JF, and Cooper CW. Ability of calcitonins to alter food and water consumption in the rat. Peptides 3: 749-755, 1982.

48.   Van-Rossum, D, Hanisch UK, and Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev 21: 649-678, 1997.

49.   Vari, RC, Adkins SD, and Samson WK. Renal effects of adrenomedullin in the rat. Proc Soc Exp Biol Med 211: 178-183, 1996.

50.   Vine, W, Beaumont K, Gedulin B, Pittner R, Moore CX, Rink TJ, and Young AA. Comparison of the in vitro and in vivo pharmacology of adrenomedullin, calcitonin gene-related peptide and amylin in rats. Eur J Pharmacol 314: 115-121, 1996.

51.   Westermark, P, Wernstedt C, Wilander E, and Sletten K. A novel peptide in the calcitonin gene related family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140: 827-831, 1986.

52.   Woltman, T, Castellanos D, and Reidelberger R. Role of cholecystokinin in the anorexia produced by duodenal delivery of oleic acid in rats. Am J Physiol Regulatory Integrative Comp Physiol 269: R1420-R1433, 1995.

Am J Physiol Regul Integr Comp Physiol 282(5):R1395-R1404


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. T. Bello, M. H. Kemm, and T. H. Moran
Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R76 - R81.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger
Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1798 - R1808.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
C. Mack, J. Wilson, J. Athanacio, J. Reynolds, K. Laugero, S. Guss, C. Vu, J. Roth, and D. Parkes
Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2007; 293(5): R1855 - R1863.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger
Ghrelin Attenuates the Inhibitory Effects of Glucagon-Like Peptide-1 and Peptide YY(3-36) on Food Intake and Gastric Emptying in Rats
Diabetes, November 1, 2006; 55(11): 3038 - 3046.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger
Intravenous infusion of glucagon-like peptide-1 potently inhibit